.png)
Fierce Pharma Asia—Congress' US-China biotech report; NIH's database ban; GSK's ABL neuroscience deal
A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over China. The NIH has blocked China's access to some health and genomics databases. GSK signed a deal worth up to $2.5 billion for ABL Bio's neuroscience technology. And more.
A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over China. The NIH has blocked China's access to some health and genomics databases. GSK signed a deal worth up to $2.5 billion for ABL Bio's neuroscience technology. And more.
